Concentración de cadenas ligeras libres en el suero y relación con algunas características de pacientes con mieloma múltiple

Van Nguyen-Thanh Phan, Loc Thi Cao, Minh Duc Tong, Trung Hoang Nguyen, Kha Van Tran, Dung Trong Le

Resumen

Introducción: La cuantificación de cadenas ligeras libres en el suero es una prueba valiosa para determinar el riesgo al momento del diagnóstico del mieloma múltiple, así como evaluar la respuesta al tratamiento y monitorear la recurrencia.
Objetivo: Determinar las características de la concentración de cadenas ligeras libres en el suero y su relación con algunas características clínicas y subclínicas en pacientes con mieloma múltiple.
Métodos: Se realizó un estudio descriptivo, retrospectivo, no controlado, en 74 pacientes con mieloma múltiple. Todos los pacientes completaron pruebas cuantitativas de cadena ligera libre en el suero κ y cadena ligera libre en suero λ.
Resultados: El mieloma múltiple de inmunoglobulina intacta representó a la mayoría de los pacientes (81 %). La mayoría de los pacientes tenían cadenas ligeras libres séricas anormales en el momento del diagnóstico (98,6 %). La concentración elevada de cadenas ligeras libres en el suero correlacionó con concentración de proteína M > 3 g/dL (p< 0,05) y no hubo correlación estadísticamente significativa entre cadenas ligeras libres en el suero elevadas y otras características clínicas y subclínicas.
Conclusión: La mayoría de los pacientes con mieloma múltiple tienen cadenas ligeras libres séricas elevadas en el momento del ingreso. Se observa correlación de cadenas ligeras libres séricas altas, con la proteína M sérica aumentada.

Palabras clave

mieloma múltiple; concentración de sLFC; sFLCκ; sFLCλ.

Referencias

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 [access: 01/11/2014]; 15(12):e538-48. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1470204514704425

Kyle RA, Rajkumar SV. Erratum: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2014 [access: 09/08/2014]; 28(4):980. Available at: https://www.nature.com/articles/leu201411

Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San MJ, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, The Journal of the American Society of Hematology. 2011 [access: 05/05/2011]; 117(18):4701-5. Available at: https://ashpublications.org/blood/article/117/18/4701/21362/Consensus-recommendations-for-standard

Jenner E. Serum free light chains in clinical laboratory diagnostics. Clinica Chimica Acta. 2014 [access: 01/01/2014]; 427:15-20. Available at: https://www.sciencedirect.com/science/article/pii/S0009898113003288

García de Veas Silva JL, Bermudo GC, Menéndez VP, Rojas Noboa JC, Kestler K, Duro MR. Prognostic value of serum free light chains measurements in multiple myeloma patients. PloS one. 2014 [access: 28/11/2016]; 11(11):e0166841. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166841

Thanh Thanh S. Research for Clinical Features of Multiple myeloma at Hematology Department of Cho Ray Hospital. Medical Journal of Ho Chi Minh City. 2011 [access: 01/11/2011]; 15(4):259-66. Available at: https://yhoctphcm.ump.edu.vn/index.php?Content=ChiTietBai&idBai=6430

Ngoc LB, Monivong Cheanh BS. Treatment efficacy of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) regimens in multiple myeloma patients with renal impairment. Vietnam Medical Journal. 2021 [access: 05/08/2021]; 505(2): 101-05. Available at: https://tapchiyhocvietnam.vn/index.php/vmj/article/view/1101/961

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). National Cancer Institute; 2012. [access: 05/08/2021]. Available at: https://seer.cancer.gov/archive/csr/1975_2009_pops09/

Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, The Journal of the American Society of Hematology. 2011 [access: 27/10/2011]; 118(17):4519-29. Available at: https://ashpublications.org/blood/article/118/17/4519/29031/Personalized-therapy-in-multiple-myeloma-according

Bora K. Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex and geography. Cancer epidemiology. 2019 [access: 01/04/2019]; 59:215-20. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1877782118307173

Lee BH, Shin SH, Min CK, Yhim HY, Kwak JY, Kim JA. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy. International journal of hematology. 2013 [access: 20/04/2013]; 97(5):634-39. Available at: https://link.springer.com/article/10.1007/s12185-013-1311-2

Khanh BQ. Study on Autologous stem cell transplantation in treatment of Multiple Myeloma and non-Hodgkin Lymphoma. PhD thesis, Hanoi Medical University; 2014. [access: 20/01/2015]. Available at: https://sdh.hmu.edu.vn/news/cID97_nghien-cuu-hieu-qua-cua-ghep-te-bao-goc-tu-than-dieu-tri-benh-da-u-tuy-xuong-va-u-lympho-ac-tinh-khong-hodgkin.html

Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, et al. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematological oncology. 2011 [access: 26/11/2011]; 30(3):156-162. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.1019

Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, et al. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leukemia & lymphoma. 2016 [access: 23/01/2017]; 57(9):2058-64. Available at: https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1124994

Wang L, Jin FY, Li Y, Sun JN, Zhang JJ, Tang R, et al. IgA type multiple myeloma, clinical features, and prognosis. Chinese medical journal. 2018 [access: 28/05/2018]; 131(10):1249-50. Available at: https://mednexus.org/doi/full/10.4103/0366-6999.231513

Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015 [access: 12/05/2015]; 29(10):2033-38. Available at: https://www.nature.com/articles/leu2015118

Rafae A, Malik MN, Zar MA, Durer S, Durer C. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring. Cureus. 2018 [access: 15/08/2018]; 10(8):[aprox. 17 scr.]. Available at: https://www.cureus.com/articles/13514-an-overview-of-light-chain-multiple-myeloma-clinical-characteristics-and-rarities-management-strategies-and-disease-monitoring

Ramakrishnan N, Jialal I. Bence-Jones Protein. Treasure Island: StatPearls Publishing; 2019. [access: 11/08/2019]. Available at: https://europepmc.org/article/NBK/nbk541035

Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood, The Journal of the American Society of Hematology. 2016 [access: 22/12/2016]; 128(25):2941-48. Available at: https://ashpublications.org/blood/article/128/25/2941/35690/Serum-free-light-chains-not-urine-specimens-should

Sthaneshwar P, Nadarajan V, Maniam JA, Nordin N, Gin GG. Serum free light chains: diagnostic and prognostic value in multiple myeloma. Clinical Chemistry and Laboratory Medicine. 2009 [access: 26/06/2009]; 47(9):1101-07. Available at: https://www.degruyter.com/document/doi/10.1515/CCLM.2009.260/html

Enlaces refback

  • No hay ningún enlace refback.




URL de la licencia: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es